Objectives: To assess changes in macrolide and ketolide resistance among Streptococcus pyogenes in Europe and to examine the relationship of resistance to antimicrobial usage.
Introduction
Macrolides provide an alternative for treating b-lactam allergic patients with a Streptococcus pyogenes infection. However, the usefulness of this class of drugs against S. pyogenes is limited in European and Asian countries with high rates of macrolide resistance. 1 -5 Macrolides inhibit protein synthesis by binding to 23S rRNA (domain V) of the 50S bacterial ribosome subunit. 6 The majority of S. pyogenes that are macrolide-resistant contain an erm gene encoding methylation of the ribosomal target or mef(A) causing efflux of the antimicrobial agent. 7 -9 Isolates with the mef(A) gene have the M phenotype: low to moderate resistance to 14-and 15-membered macrolides, but are susceptible to 16-membered macrolides, lincosamides and streptogramin B. 7 The erm gene confers macrolide, lincosamide and streptogramin B resistance [constitutive MLS B (cMLS B ) phenotype-usually erm(B)] or may require macrolide exposure for clindamycin resistance to become apparent [inducible MLS B (iMLS B ) phenotypeusually erm(A)]. 8, 9 Mutations in 23S rRNA and ribosomal proteins have occasionally been associated with macrolide resistance in S. pyogenes. 10 -12 Ketolides are a new class of antimicrobials derived from erythromycin with 10-fold greater ribosomal binding affinity due to secondary interaction with domain II. 13 The first available ketolide, telithromycin, is an effective therapy for macrolide-resistant Streptococcus pneumoniae, but has variable activity against S. pyogenes isolates with cMLS B phenotype expression. 14 -16 The overall prevalence of ketolide resistance in the S. pyogenes population has been relatively low. 17, 18 The purpose of this study was to assess changes in macrolide and ketolide resistance rates among S. pyogenes clinical isolates from Europe. The second goal was to determine the relationship of macrolide and ketolide resistance to antimicrobial usage in Europe. Telithromycin-resistant isolates were further characterized by PFGE to determine genetic relatedness and by PCR to detect macrolide resistance genotypes.
Methods
Isolates Clinically significant S. pyogenes isolates from unique patients were obtained from 65 medical centres in 15 countries (Denmark, Finland, France, Germany, Italy, Netherlands, Norway, Spain, Sweden, UK, Croatia, Hungary, Poland, Slovak Republic and Slovenia) during 2002-03 (n ¼ 2165) and 2004-05 (n ¼ 2333). Forty-four medical centres contributed isolates during both study periods. The susceptibility profiles of the 2002-03 isolates were reported previously. 1 Data regarding identification methods used by participating laboratories were not collected. The identification of the isolates was confirmed in the central laboratory by colony morphology, b-haemolysis and a positive PYR test followed by storage at 2708C.
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Susceptibility testing
Susceptibility testing was performed using the CLSI broth microdilution method in Mueller -Hinton broth supplemented with 3% lysed horse blood. 20 The antimicrobial agents tested were azithromycin, cefdinir, clarithromycin, clindamycin, erythromycin, levofloxacin, penicillin and telithromycin. CLSI MIC breakpoints for 'Streptococcus spp. other than S. pneumoniae' were applied. 21 The CLSI interpretive criteria for S. pneumoniae were used for cefdinir and telithromycin.
21 S. pneumoniae ATCC 49619 was used for quality control.
Antimicrobial usage
The relationship of erythromycin and telithromycin resistance in 2004-05 to outpatient antimicrobial use in 2002-03 [European Surveillance of Antimicrobial Consumption (ESAC) data] was assessed by linear regression analysis. The ESAC project applies the Anatomic Therapeutic Chemical classification system with measurement by the defined daily dose (DDD) unit (endorsed by the World Health Organization) per 1000 inhabitants per day. Detailed descriptions of the ESAC project have been published previously.
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Macrolide resistance phenotype
The double disc diffusion D-zone test was performed on telithromycin-resistant isolates with a clindamycin MIC 0.5 mg/L (susceptible or intermediate) using 15 mg erythromycin and 2 mg clindamycin discs according to CLSI guidelines (12 mm apart).
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Blunting of the inhibition zone around the clindamycin disc adjacent to the erythromycin disc was interpreted as the iMLS B phenotype. Clindamycin-susceptible isolates with no blunting were assigned the M phenotype. Resistance to erythromycin and clindamycin was considered the cMLS B phenotype.
Macrolide resistance genotype
A multiplex PCR for erm(A), erm(B) and mef(A) was performed on all telithromycin-resistant isolates as previously described. 25 -27 Isolates with negative PCR results were analysed for mutations in domain V of 23S rRNA genes according to published methods. 10, 12, 28 Pulsed-field gel electrophoresis
Telithromycin-resistant isolates were characterized by PFGE after DNA digestion with ApaI (New England Biolabs) using CHEF-DR II (Bio-Rad) at 148C and 200 V for 23 h (initial forward time, 1 s; final forward time, 17 s). Ethidium bromide stained gels were analysed using Bionumerics TM software (Applied Maths, Kortrijk, Belgium). The dendrogram was constructed using the unweighted pair group method with arithmetic averages and the DICE coefficient (1.0% optimization, 1.0% position tolerance). Isolates were assigned to the same PFGE pattern if their profile differed by three bands or less (similarity coefficient of 84% on the dendrogram). 29 
Statistical analysis
The x 2 test with Yates' correction was used to evaluate the significance of dichotomous values. Only P values ,0.05 were considered significant.
Results
The types of specimens yielding S. pyogenes isolates in 2002 -03 (n ¼ 2165) and 2004 -05 (n ¼ 2333) were similar: throat (67%, 64%), skin and soft tissue (21%, 20%), upper respiratory tract (6%, 6%), blood cultures/sterile site (4%, 6%) and other (2%, 4%). The age distribution of the patients for the two periods was 0 -5 (19%, 24%), 6 -20 (26%, 33%), 21-64 (27%, 35%), 65 years (5%, 6%) and unknown (23%, 2% (Table 4 ). The significant change in telithromycin resistance rates was evident in Western (from 1.9% to 4.5%) and Eastern Europe (from 1.7% to 6.7%) (P , 0.0001). The 15 isolates with a telithromycin MIC 32 mg/L were all from the 2004 -05 surveillance period. Four countries had significant increases in telithromycin resistance (Table 2) : Italy (3.7% to 10.1%, P ¼ 0.009), Croatia (2.1% to 11.8%, P ¼ 0.02), Slovak Republic (0% to 36.4%, P , 0.0001) and Slovenia (3% to 12.3%, P ¼ 0.03).
All 162 telithromycin-resistant isolates (both time periods) were high-level erythromycin resistant (MIC 64 mg/L) and 90.7% were also clindamycin resistant (cMLS B phenotype) ( Table 5 ). D-zone testing performed on the 15 telithromycinresistant isolates with a clindamycin MIC 0.5 mg/L revealed (Figure 2) .
For Eastern Europe, no significant association between antimicrobial use and resistance with S. pyogenes was found (R 2 , 0.5; consumption data are given in Table 2 ). The 162 telithromycin-resistant isolates represented 42 different PFGE patterns with 68.5% of the isolates in eight major PFGE clones (A -H) containing six or more isolates ( The predominant macrolide resistance genotype detected among the 162 telithromycin-resistant isolates was erm(B) (n ¼ 155, 95.7%) and included the 15 isolates with iMLS B phenotypes (Table 5 ). The mef(A) gene was also detected in two of the isolates with erm(B). Seven telithromycin-resistant isolates were negative for erm(B), erm(A) and mef(A) genes. A 23S rRNA A2058T mutation was detected in two of these isolates. Both isolates with the A2058T mutation were from Croatia, but had unrelated PFGE profiles (unique and PFGE H).
Discussion
In 2004 -05, the prevalence of macrolide resistance in individual countries was highly variable ranging from 0% in the Netherlands to 40.9% in the Slovak Republic ( 18 In 2004, a significant increase in cMLS B phenotype to 30.5% of the macrolide-resistant isolates was noted in Spain. 30 The overall telithromycin resistance rate of 5.2% in the current study was a significant increase from the 2002 -03 rate of 1.8%. In 2004 -05, there were four countries with telithromycin resistance rates above 10% (Italy, 10.1%; Croatia, 11.8%; Slovenia, 12.3%; and Slovak Republic, 36.4%)-a sharp contrast to 2003 -04 when the telithromycin resistance rate for each individual country was ,4%. A 1999 -2000 study reported telithromycin resistance rates (4 mg/L) of 2.1% in Croatia, 0% in Slovenia and 3% in the Slovak Republic. 18 The presence of erm(B) in the majority of telithromycinresistant S. pyogenes isolates (95.7%) in this study is consistent with observations made by others. 16, 17, 27, 34, 35 However, the low telithromycin MICs for virtually all S. pneumoniae and at least some erm(B)-positive S. pyogenes isolates suggest additional factors are needed to confer telithromycin resistance. For example, a 1999 -2003 Belgium study described macrolideresistant S. pyogenes isolates with the cMLS B phenotype which had telithromycin MICs ranging from 0.0075 to 32 mg/L with an MIC 50 of 1 mg/L; only 10% of isolates with erm(B) had telithromycin MICs 4 mg/L. 36 In our study, the proportion of The erm genes encode methylation of the A2058 nucleotide of 23S rRNA where macrolide and ketolide antibiotics bind susceptible strains. There is a variation among erm genes-they may monomethylate or dimethylate the A2058 position. 37 Using mass spectrometry, Douthwaite et al. 38 demonstrated correlation of telithromycin resistance with degree of methylation by erm(B): isolates with fully dimethylated A2058 had the highest telithromycin MICs while a large proportion of rRNA in ketolide-susceptible strains was monomethylated. Incubation of ketolide-susceptible erm(B) strains with erythromycin (0.5 mg/L) increased the degree of dimethylation and telithromycin MICs. 38 An H118R (A677G) mutation has been detected in the erm(B)-coding region by two independent investigators in 12 telithromycin-resistant S. pyogenes isolates. 17, 36 Mutations in erm(B) may increase the degree of rRNA dimethylation at A2058 or alter methylase specificity to allow methylation of additional telithromycin binding sites. 36 Of the seven telithromycin-resistant isolates without erm(B), two unrelated strains from Croatia had 23S rRNA A2058T mutations that have been previously associated with macrolide resistance in pneumococci. 39 The A2058G 23S rRNA mutations that have been reported in macrolide-resistant 10, 11 and telithromycin-resistant S. pyogenes 27, 40 were not detected. The significant associations found for erythromycin resistance in 2004 -05 with macrolide use in 2002 -03 in Western Europe have also been reported in Finland, 41 Spain 42 and Italy. 43 A more direct link between antibiotic use and the emergence of resistance has been demonstrated by a randomized, double-blind study that found an increased proportion of macrolide-resistant streptococci colonizing the pharynx of volunteers after azithromycin or clarithromycin treatment in comparison to placebo. 44 The association between macrolide use and telithromycin resistance is not surprising given the increased rRNA dimethylation at A2058 and decreased ketolide susceptibility demonstrated in vitro for S. pyogenes strains after exposure to subinhibitory concentrations of erythromycin. 38 The lack of significant association between macrolide use and our 2004 -05 resistance data for Eastern Europe is likely due to the lower number of isolates collected from those countries. The substantial number of countries without any consumption of telithromycin as documented by EUCAST (Table 2 ) hindered our ability to assess the potential association between telithromycin use and resistance.
In conclusion, we found significant increases in telithromycin resistance among S. pyogenes in Europe from 2002 -03 to 2004 -05. Although the macrolide-resistance rate was stable, the prevalence of cMLS B phenotype strains and telithromycin resistance in this population has increased over time. Correlation of antibiotic use with resistance rates in Western Europe supports macrolide use as a factor in the emergence of ketolide resistance. The presence of predominant clones among the telithromycinresistant S. pyogenes population suggests clonal expansion is also contributing to the observed increase in ketolide resistance.
